|
Volumn 13, Issue 11, 2012, Pages 1022-1025
|
Therapeutic potential of targeting IL-17
|
Author keywords
[No Author keywords available]
|
Indexed keywords
BRODALUMAB;
INTERLEUKIN 17;
INTERLEUKIN 17 ANTIBODY;
INTERLEUKIN 17F;
INTERLEUKIN 25;
INTERLEUKIN 27;
IXEKIZUMAB;
TUMOR NECROSIS FACTOR ANTIBODY;
TUMOR NECROSIS FACTOR INHIBITOR;
ADAPTIVE IMMUNITY;
ALLERGIC ENCEPHALOMYELITIS;
ALLERGY;
ANKYLOSING SPONDYLITIS;
ASTHMA;
AUTOIMMUNITY;
CD4+ T LYMPHOCYTE;
CONFERENCE PAPER;
CROHN DISEASE;
CYTOKINE RELEASE;
CYTOKINE RESPONSE;
DRUG TARGETING;
ENTERITIS;
GAMMA DELTA T LYMPHOCYTE;
HUMAN;
IMMUNOPATHOGENESIS;
IMMUNOREGULATION;
INNATE IMMUNITY;
MUCOSAL IMMUNITY;
NONHUMAN;
PRIORITY JOURNAL;
PROTEIN FUNCTION;
PROTEIN INDUCTION;
PROTEIN TARGETING;
PSORIASIS;
TH17 CELL;
TUMOR MICROENVIRONMENT;
ULCERATIVE COLITIS;
ADAPTIVE IMMUNITY;
ANIMALS;
ANTIBODIES;
AUTOIMMUNE DISEASES;
AUTOIMMUNITY;
BACTERIAL INFECTIONS;
HUMANS;
IMMUNITY, INNATE;
IMMUNOLOGIC FACTORS;
INTERLEUKIN-17;
MICE;
MOLECULAR TARGETED THERAPY;
MYCOSES;
NEOPLASMS;
RECEPTORS, INTERLEUKIN-17;
TH17 CELLS;
VIRUS DISEASES;
|
EID: 84867736584
PISSN: 15292908
EISSN: 15292916
Source Type: Journal
DOI: 10.1038/ni.2450 Document Type: Conference Paper |
Times cited : (45)
|
References (24)
|